

For personal use only



COMPANY PRESENTATION | 20th JULY 2018

novitahealthcare.com.au



WHAT WE DO AND WHY WE DO IT

Novita is building and commercialising digital therapeutics and screening tools.

Our solutions deliver positive health and wellbeing outcomes

- **Mission:** We strive to deliver market leading, patient outcome focused digital medicine
- **Values:** Focus on innovation, collaboration, empathy, community benefit
- **Vision:** Our Vision is to be a global leader in early childhood intervention: by building digital screening tools and therapeutics that forever change health, education and life outcomes



THE COMPANY


OUR CORE HOLDING IS TALI HEALTH



- **TALI Health:** company was formed to commercialise intellectual property from an ongoing 20+ year Monash University neuroscience research project;
- **TALI Train: A patented digital platform technology**¹ providing direct therapeutic activity, delivered not through a pill, but through a game based experience via an app on a tablet or smartphone
- **TALI Train is available NOW:** designed for children with attention difficulties both clinical (e.g. children with an autism spectrum disorder) and non-clinical populations between 3-8 years of age for early intervention - **personalised medicine that treats the underlying cause of attention difficulties**

OUR CURRENT AND FUTURE PATHWAYS... PRODUCT NOW AND A PIPELINE TO GROWTH

Digital medicine strategy – Focus on domestic growth before expanding into global markets, allowing us to leverage off similar marketing channels and insurance schemes for our current and future technologies.



For personal use only

BUT WHY? SCIENCE AND TECHNOLOGY COMBINING TO DELIVER OPTIMISED MEDICINE

Digital screening and therapeutics are tools, such as mobile apps and platforms, whose interventions may complement or replace traditional medicine - >USD\$9B market by 2025²

- **Digital therapeutics are a new category of apps** that help treat medical conditions to improve long-term health outcomes
- **Attention** is one of the first cognitive skills to develop in children and plays a vital role in the development of more complex skills such as memory and language - important prerequisites for learning
- **Early intervention** is crucial in preventing and limiting the detrimental long-term impact of attention difficulties
- **Mobile app-based digital screening and treatments can be delivered with scale and cost benefits.** Millions of children stand to benefit whilst potentially saving insurers, governments and parents billions of dollars annually

ATTENTION DIFFICULTIES – A GLOBAL PROBLEM

Globally **136 million** children have severe attention difficulties

- 400,000 children in Australia have severe attention difficulties ³
- Heightened risk for children with neurodevelopmental disorders
- 40% of children who are otherwise typically developing at the age of four have some degree of attention difficulty
- Children with attention difficulties are 40% less likely to graduate from high school
- \$24 billion dollars is the annual cost of childhood inattention in Australia ⁴
- Impact on families is immeasurable

3. NHMRC, The Royal Australasian College of Physicians. *Australian Guidelines on ADHD (2009)*

4. Buescher A.V., Cidav Z., Knapp M., Mangell D.S. *JAMA Pediatr* 168(8):721-728 (2014). *Economic Cost of Autism Spectrum Disorders in Australia*. Synergies Economic Consulting (2011)

TALI Train PROVIDES CLINICIANS AND PARENTS WITH A NEW OPTION - “A NEW TOOL IN THE TOOLKIT”

- Psychostimulant medication is the most common treatment for attention difficulties and has been shown to be effective in the short term. **However;**
 - the long term impacts are still being investigated;
 - there can be adverse side effects;
 - It’s a one size fits all approach; and
 - It is limited as an early intervention option (not typically administered under the age of 7 years)

TALI Train is a new early intervention option and is complimentary to existing treatments

Think of a new healthcare world - instead of ONLY prescription medicines (e.g. Ritalin for ADHD) - **think prescription digital therapeutics** (e.g. TALI Train for Autism and ADHD)

For personal use only



TALI Train – A DIGITAL, ADAPTIVE MEDICINE WITH PROVEN RESULTS

A Breakthrough In Early Childhood Intervention

TALI TECHNOLOGY



Breakthrough Technology

TALI is a breakthrough program proven to improve childhood attention and learning outcomes



Scientific Approach

The TALI exercises were designed by neuroscientists with over 25 years of experience.



Detailed Reports

The TALI web portal provides instant access to the child's daily progress and performance via built-in analytics.



Training Schedule

Designed as a five-week clinical intervention, the program is accessed via a home-based tablet, making it available to users across a wide range of socio-demographic groups and geographic locations.



Evidence Based

The benefits of TALI are proven and were evaluated in a gold standard clinical trial. This research is published in highly regarded international journals.



Adaptive

Using a special algorithm, each TALI exercise adapts in difficulty in real time to ensure that children are always working at the optimum level for them.



SCIENCE MEETS DESIGN TO DELIVER CLINICAL OUTCOMES

TALI Train – neuroscientists combining with game designers to deliver a world leading, game based digital treatment. The program is;

- **Evidence based** – this is not just another brain training app. This is a program developed and evaluated by cognitive neuroscientists who specialise in childhood development;
- **Adaptive** – tailored to every child. It's personalised medicine at its best;
- **At home use** – allows parent involvement in the treatment and is fun for the child; and
- **Early intervention** – lasting benefit can be obtained for children 3 to 8 years of age



A GAME BASED PROGRAM THAT IS FUN AND REWARDING WITH ALGORITHMS THAT DELIVERS A CLINICALLY PROVEN TREATMENT

The TALI Exercises

TALI TRAIN

SELECTION



This exercise trains children to attend to relevant information whilst filtering out distractions.

CONTROL



Children develop the ability to choose what they attend to and what to ignore.

INHIBITION



This exercise trains children to act in a less impulsive manner.

FOCUS



Children develop the ability to maintain their attention on a task over a prolonged period of time.

THE EVIDENCE – TALI IS EFFECTIVE FOR CHILDREN WITH DEVELOPMENT DISORDERS AS WELL AS TYPICALLY DEVELOPING CHILDREN



Results of a rigorous double-blind randomised controlled trials investigating the effectiveness of TALI Train have shown that children who used TALI Train vs another touchscreen program for the same period of time are as follows ⁵:

Children with developmental disorders:

- Achieved significantly greater gains in selective attention immediately after training [b= -1.68, p<0.05, d=0.24]
- Attentional gains were maintained up to three months after training had ceased [b= -1.87, p<0.05, d=0.26]
- Showed significantly greater improvements in numeracy skills three months after training had ceased [b= 1.94, p<0.05, d=0.15].
- These findings are part of one of the few studies that have successfully promoted transfer to untrained skills

Typically developing children:

- Had a significant reduction in ADHD symptoms in the classroom immediately after training [b=-13.53, p=.001, d=0.86]



THE IMPORTANCE OF EARLY INTERVENTION

Our key audiences understand the large unmet market opportunity for the non-pharmaceutical treatment of childhood attention disorders – TALI is positioned at the forefront of this opportunity



CLINICIANS

It is clinically proven and well-known amongst the clinical community that early intervention provides the best outcomes for patients with attention difficulties. However, clinicians are searching for non-drug based therapies to use in the early stages that provide long term results



SCHOOLS

Early intervention will present improvements in learning for children with attention difficulties in the initial stages of their education, reducing pressure on the schooling system to offer extensive special needs assistance



PARENTS

There is an opportunity for parents to positively impact their child's future development if signs of attention difficulties are spotted and diagnosis / treatment is sought

For personal use only

EXAMPLES OF CHANNELS TO PROVIDE TALI TRAIN TO OUR KEY AUDIENCES – WE ARE A SaaS BUSINESS



TALI is available on the Apple App Store or Google Play for immediate download



Registered NDIS Provider

TALI Health is a registered NDIS provider – children identified with Autism Spectrum Disorder and other developmental disorders requiring early intervention are **eligible for support under the NDIS (no “out of pocket” cost)**



TALI Health partners with ECIA to ensure healthcare professionals understand the benefits of TALI Train so that they can deliver it to their patients

THE IMPORTANCE OF AN INCLUSIVE, DIRECT ACCESS MODEL – TALI TRAIN IS ANOTHER “TOOL IN THE TOOLKIT”

Healthcare professionals, educators and parents are included as involvement is key to ensure compliance to the TALI treatment program and appropriate ongoing management of the child



CLINICIANS

Healthcare professionals become TALI Certified Providers and deliver TALI Train to their patients for \$399 per 5 week program – maintaining the patient/clinician relationship



SCHOOLS

Educators can deliver TALI Train on a single use basis for \$399 per 5 week program or schools/districts/states can purchase a “site licence” from TALI health



PARENTS

Parents can download the app direct from the iTunes App Store or Google Play Store for \$399 or via a part payment plan over the 5 week program

TO DRIVE THIS STRATEGY WE ARE MAKING CHANGES - DIVESTMENT OF NEWLY


Novita has entered into a “Heads of Agreement” to sell Newly to HealthcareLink* – due diligence underway

- **HealthcareLink (HCL)** is an award winning, online marketplace for jobs and careers in the healthcare and medical industry
- The combined entity will **create a powerful human resource placement solution** in the healthcare sector, driven by deep domain experience of the combined teams and a unique SaaS technology offering
- Post completion of transaction, **Novita will subscribe to and obtain a 10% equity holding in HCL** and obtain a position on the **HCL board**
- **Novita’s view is** that this will provide Newly with the best chance to reach the forecast potential of the business whilst allowing Novita to focus on its core strategy with TALI Health

COMBINED POWER TO TACKLE A MASSIVE OPPORTUNITY

For personal use only

Recruitment spend in Healthcare is \$1.5B per annum⁶ - HealthcareLink and Newly combined will create a differentiated and market leading offer



NOVITA BOARD COMMITTED TO GROWTH AND THE LONG TERM

For personal use only



Mark Simari
Chairman

- Significant experience on boards in privately held and ASX-listed companies
- Responsible for driving growth strategies including acquisitions, capital raising, restructuring, and driving strategic and business planning processes



Jefferson Harcourt
Non-Executive Director

- Founder of Grey Innovation, significant product development and commercial expertise
- Sits on a number of private technology company boards in medical device and security markets



Glenn Smith
Managing Director

- Over twenty years experience in leading customer-centric businesses in periods of rapid growth
- Seasoned executive who has held senior roles in strategy, investment, R&D, marketing, sales and operations

NOVITA INVESTMENT HIGHLIGHTS

GLOBAL BUSINESS OPPORTUNITY

- TALI Train (ARTG Class 1 medical device) is a **breakthrough game-based training technology focused on treating childhood attention deficit difficulties**
- **136 million children have clinical attention difficulties (e.g. ADHD).** Children experience non-clinical attention difficulties, and can also benefit from TALI Train.
- **Divestment of Newly** allows Novita to focus on digital therapeutics and screening strategy
- **A\$1.2m Australian Government CRC grant** will support accelerated development and commercialisation of TALI Detect through to the end of 2019. This attention screening tool, which complements and builds on TALI Train
- **Novita will build a pipeline of potential technology opportunities** which places Novita in an exciting phase of growth

CORPORATE OVERVIEW

Company profile

- Novita’s Vision is to be a global leader in early childhood intervention: by building digital screening tools and therapeutics that forever change health, education and life outcomes
- Our solutions deliver positive health and wellbeing outcomes

Share price performance (1 year)



Financial information

Share price (16-July-18)	A\$0.033
Number of shares	359.4m
Market capitalisation	A\$11.9m
Cash (30-Jun-18)	A\$1.2m
Debt (30-Jun-18)	No debt
Enterprise value	A\$10.7m

Source: Automic

Notes:

1 Excludes 23.1m unlisted options on issue at various vesting and expiry dates with A\$0.03 exercise price and subject to operational criteria

Key shareholders

P & D DIAMOND SUPER FUND A/C	8.35%
GREY INNOVATION HOLDINGS PTY LTD	5.82%
MOUNTFORD PHL PTY LTD	4.38%
THREE ZEBRAS PTY LTD	4.31%
MOONAH CAPITAL PTY LTD	3.30%
Top 20 shareholders (12-July-18)	52.09%

OFFER

For personal use only

OVERVIEW	
Issuer	Novita Healthcare Limited (“Novita Healthcare”, “NHL” or the “Company”)
Listing	ASX:NHL
Securities on Issue	359,444,132 ordinary shares 23,177,766 Director/Employee options
Last Close Price	A\$0.033 ¹
Market Capitalisation	A\$11.9m ¹
OFFER DETAILS	
Lead Manager	Shaw and Partners Limited
Transaction	Placement of up to approximately 89.8m new ordinary fully paid shares (“Offer Securities”) at [A\$0.031] per security (“Offer Price”) to raise up to ~[A\$2.78m] (“the Offer”).
Offer Price	[A\$0.031]
Pricing Discounts	6.06% discount to last close of A\$0.033 ¹ 6.06% discount to 5 day VWAP of A\$0.033
Use of funds	The net proceeds of the placement will be used for: <ul style="list-style-type: none"> • Direct to consumer marketing and sales activities • International expansion for TALI Train • Initial TALI Detect pilot programs • HealthcareLink capital subscription as part of divestment of Newly Pty Ltd \$500k

1. The last close which has been adopted is 16 July 2018.

DISCLAIMER

Some of the statements in this presentation constitute “forward-looking statements” that do not directly or exclusively relate to historical facts.

These forward-looking statements reflect Novita Healthcare Limited’s current intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors, many of which are outside Novita Healthcare Limited’s control. Important factors that could cause actual results to differ materially from the expectations expressed or implied in the forward-looking statements include known and unknown risks.

Because actual results could differ materially from Novita Healthcare Limited’s current intentions, plans, expectations, assumptions and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

For personal use only



Investors please contact: Glenn Smith, Managing Director
Email: gsmith@novitahealthcare.com.au

